02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
15:35 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

FDA grants Amgen's Blincyto accelerated approval for MRD-positive ALL

FDA granted accelerated approval to Blincyto blinatumomab to treat B cell precursor acute lymphoblastic leukemia in patients who are in remission but still have minimal residual disease (MRD). The bispecific T cell engager (BiTE) against...
18:46 , Mar 29, 2018 |  BC Extra  |  Company News

Accelerated approval for Blincyto in new ALL indication

FDA granted accelerated approval to Blincyto blinatumomab to treat B cell precursor acute lymphoblastic leukemia in patients who are in remission but still have minimal residual disease (MRD). The bispecific T cell engager (BiTE) against...
21:10 , Mar 7, 2018 |  BC Extra  |  Company News

FDA panel backs Blincyto in ALL subpopulation

FDA’s Oncologic Drugs Advisory Committee voted 8-4 that data from a Phase II trial showed the benefits of Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) outweigh its risks in treating minimal residual disease (MRD)-positive B cell...
20:56 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

March 7 ODAC meeting for Amgen's Blincyto

Amgen Inc. (NASDAQ:AMGN) said FDA’s Oncologic Drugs Advisory Committee will meet on March 7 to discuss an sBLA for Blincyto blinatumomab to treat minimal residual disease (MRD)-positive B cell precursor acute lymphoblastic leukemia (ALL). The...
23:48 , Feb 14, 2018 |  BC Extra  |  Company News

March 7 ODAC meeting for Amgen's Blincyto

Amgen Inc. (NASDAQ:AMGN) said FDA’s Oncologic Drugs Advisory Committee will meet on March 7 to discuss an sBLA for Blincyto blinatumomab to treat minimal residual disease (MRD)-positive B cell precursor acute lymphoblastic leukemia (ALL). The...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
22:35 , Oct 6, 2017 |  BioCentury  |  Finance

Cancer aggregator

MPM Capital launched Cullinan Oncology LLC to aggregate cancer assets that on their own would be too risky to build a company around. The firm believes by amassing up to 10 projects at any given...
19:21 , Oct 6, 2017 |  BC Week In Review  |  Financial News

Cullinan raises $150M in series A

On Oct. 3, Cullinan Oncology LLC (Cambridge, Mass.) raised $150 million in a series A round led by the UBS Oncology Impact Fund -- which is managed by MPM Capital -- and F2 Ventures. MPM...